Selank: Research, Mechanism, and Clinical Evidence for Anxiety and Cognition

What Is Selank?

Selank is a synthetic heptapeptide developed in Russia and approved there as an anxiolytic, studied for its dual anxiolytic and cognitive-enhancing properties.

Selank (TP-7) is a seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence that enhances metabolic stability and introduces neurotropic properties.

Selank is approved in Russia as an anti-anxiety medication and marketed as a nasal spray for generalized anxiety disorder (GAD). It has been in clinical use in Russia since the early 2000s, though it remains unapproved in the United States, the European Union, and most other markets.

What makes Selank unusual in pharmacology is its reported dual action: reduction of anxiety without sedation, combined with cognitive enhancement. This profile is rare. Benzodiazepines reduce anxiety but impair cognition; stimulants enhance cognition but may increase anxiety.

Who this page is for, and who it isn’t for

This page is for researchers, clinicians, and individuals seeking a balanced summary of the available Selank literature. Much of the published clinical data originates from Russian research groups, and some studies have limited English-language accessibility. This page is not a treatment guide, and it is not a substitute for consultation with a qualified healthcare provider about anxiety or cognitive concerns.

How Selank Is Thought to Work

Selank appears to act through multiple neurotransmitter systems, including GABAergic modulation, serotonin pathway effects, and BDNF upregulation.

GABAergic Modulation

Selank modulates the GABAergic system, the primary inhibitory neurotransmitter system in the brain:

• Allosteric modulation of GABA-A receptors. Selank appears to enhance GABA binding to GABA-A receptors, potentiating inhibitory signaling without directly activating the receptor. Conceptually this is similar to benzodiazepines, but through a different binding mechanism.

• No benzodiazepine binding site activity. This is a critical distinction. Selank does not interact with the benzodiazepine binding site, which is associated with the tolerance, dependence, and withdrawal that characterize benzodiazepine drugs.

• Gene expression effects. Chronic Selank administration has been shown to alter the expression of genes encoding GABA-A receptor subunits in the hippocampus (Kasian et al., 2017).

Serotonergic Effects

Selank influences serotonin metabolism through an indirect pathway:

• It inhibits enkephalinase enzymes that degrade enkephalins (endogenous opioid peptides) (Zozulya et al., 2008).
• Increased enkephalin levels modulate serotonergic neurotransmission.
• The downstream effect is stabilized serotonin signaling, which may contribute to mood regulation and anxiolysis.

BDNF Upregulation

Selank has been shown to increase expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, a brain region critical for learning, memory, and emotional regulation. BDNF is among the most important molecules for neuroplasticity, synaptic strengthening, and neuronal survival (Inozemtseva et al., 2008).

Increased BDNF expression likely contributes to both the cognitive-enhancing and anxiolytic effects attributed to Selank.

Immunomodulatory Effects

As a tuftsin analog, Selank retains immunomodulatory properties:

• Enhances natural killer (NK) cell activity
• Modulates cytokine expression (IL-6, IFN-γ)
• May support immune function during periods of stress, which typically suppresses immunity

This immune–neuro crossover adds a dimension not seen in most anxiolytic compounds. It also connects Selank conceptually to other immunomodulatory peptides such as thymosin alpha-1 and KPV, though through different mechanisms.

Broad Gene Expression Modulation

Gene expression studies have found that Selank modulates the expression of 36 or more genes related to inflammation regulation, neurotransmitter signaling, apoptosis, ion channel function, and neuroprotection. This broad profile suggests a systems-level modulatory effect rather than a single-target pharmacological action.

What the Research Shows

The clinical evidence for Selank comes primarily from Russian research groups. While the data is intriguing, the limited independent replication outside Russia is an important caveat.

Clinical Trials (Conducted in Russia)

Generalized Anxiety Disorder. In a clinical study of patients with GAD, Selank nasal spray (0.15% solution, 3 drops per nostril, 3 times daily for 14 days) produced significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores. The anxiolytic effect was reported as comparable to medazepam (a benzodiazepine) but without sedation, cognitive impairment, or withdrawal effects (Zozulya et al., 2008).

Cognitive Performance. Studies in healthy volunteers showed Selank improved attention, short-term memory, and information processing speed. EEG analysis revealed increased alpha rhythm power (associated with relaxed alertness) and decreased theta activity (associated with drowsiness).

Anxiety with Cognitive Deficits. In patients with anxiety disorders accompanied by cognitive complaints, Selank reportedly improved both anxiety scores and neuropsychological test performance simultaneously, supporting the dual anxiolytic-nootropic profile.

It is important to note that many of these studies were published in Russian-language journals with limited English translation and limited methodological detail available for independent review.

Preclinical Animal Data

• Learning and memory. Selank improved performance in passive avoidance tests and Morris water maze paradigms in rodent studies. The effect persisted after drug cessation, suggesting lasting neuroplastic changes.
• Stress response. In restraint stress models, Selank normalized stress hormone levels and prevented stress-induced behavioral deficits.
• Neuroprotection. Selank showed protective effects against neurotoxic insults in cellular and animal models.

Limitations of the Evidence

• Most clinical data originates from a single country (Russia) and a limited number of research groups.
• Russian clinical research standards may differ from those of the FDA or EMA.
• Large-scale, multi-center, placebo-controlled trials meeting Western regulatory standards have not been published.
• Long-term safety data (beyond 6 months of continuous use) is limited.
• Drug interaction studies are sparse.

How Selank Compares to Related Compounds

Selank is often discussed in relation to other nootropic and anxiolytic peptides.

• Semax is Selank’s “sister peptide,” also developed at the Russian Academy of Sciences. Semax is derived from the ACTH(4-10) peptide family rather than tuftsin. While both are classified as nootropics, Semax is generally described as more stimulating (dopaminergic), whereas Selank is more calming (GABAergic). Semax may increase anxiety in sensitive individuals; Selank is specifically anxiolytic.

• DSIP (Delta Sleep-Inducing Peptide) is another peptide with neuromodulatory properties. While DSIP primarily targets sleep architecture and stress hormone modulation, it is sometimes discussed alongside Selank for anxiety-related sleep problems.

• Epithalon addresses a different dimension of brain health (pineal gland function and melatonin production) and is sometimes mentioned alongside Selank in the context of broader neurological support.

• L-theanine is a widely available, mild, non-sedating anxiolytic amino acid. It is considerably weaker than Selank but far more accessible, better studied in Western research settings, and may serve as a reasonable starting point before considering peptides.

Community-Reported Protocols

Community-reported protocols reflect the Russian clinical dosing literature and community experience. These should not be interpreted as recommendations.

Intranasal (Most Common Route, Clinically Used in Russia)

• Formulation: 0.15% Selank nasal spray
• Reported dose: 2–3 drops per nostril, 3 times daily
• Approximate dose per administration: 200–400 mcg
• Reported daily total: Approximately 1–2 mg
• Reported duration: 14–21 day courses, with breaks between courses
• Rationale for intranasal route: Provides access to the central nervous system via olfactory and trigeminal nerve pathways, potentially achieving higher brain concentrations than systemic administration. See the administration routes guide for more on how delivery method affects peptide activity.

Subcutaneous Injection (Community Protocol)

• Reported dose: 250–500 mcg per injection
• Reported frequency: 1–2 times daily
• Reported duration: 14–21 days
• Reconstitution: Standard bacteriostatic water

Sublingual

Some community members report efficacy with sublingual administration (holding solution under the tongue), though this route has less clinical validation than intranasal.

Cycling

Russian clinical protocols recommend courses of 14–21 days followed by breaks. Community protocols typically follow 3 weeks on, 1–2 weeks off. Tolerance has not been a well-documented issue with Selank, but the cycling approach is widely followed.

Side Effects and Safety Considerations

Selank has a mild reported side effect profile in clinical use, though the data comes primarily from Russian clinical experience.

Reported Side Effects

• Nasal irritation. With intranasal use; mild and transient.
• Allergic reactions. Rare and typically mild.
• Minimal sedation. Despite anxiolytic effects, sedation is uncommon at reported doses.

Notable Safety Characteristics

• No dependence or withdrawal documented. Unlike benzodiazepines, Selank does not appear to produce physical dependence.
• No cognitive impairment. The drug is reported to enhance cognition rather than impair it.
• No rebound anxiety. Discontinuation does not appear to produce anxiety worse than baseline.
• No significant hormonal effects. Selank does not appear to affect cortisol, testosterone, estrogen, or thyroid hormones at reported doses.

Limitations

• Most safety data is from Russian clinical experience; independent Western safety studies are lacking.
• Long-term safety data beyond 6 months is limited.
• Drug interaction studies are sparse. Caution is warranted when combining with psychiatric medications.

Regulatory and Legal Status

Russia

Approved as an anti-anxiety medication. Available as a nasal spray.

United States

Not FDA-approved. Available as a research chemical. Not a controlled substance.

European Union

Not approved. Available as a research chemical in most EU countries.

WADA

Selank is not currently listed on the WADA Prohibited List.

Frequently Asked Questions

Is Selank addictive?

Based on available data, no. Unlike benzodiazepines (alprazolam, diazepam, etc.), Selank does not appear to produce dependence, tolerance, or withdrawal. It does not interact with the benzodiazepine binding site, which is the molecular basis for benzodiazepine addiction.

How quickly does Selank work?

Intranasal Selank is reported to produce noticeable anxiety reduction within 5–15 minutes for acute effects. Cognitive benefits may take several days of consistent use to become apparent, as they likely depend on BDNF-mediated neuroplastic changes.

Can Selank be used alongside antidepressants?

Formal drug interaction data is limited. In Russian clinical practice, Selank has reportedly been used alongside various medications, but formal interaction studies meeting Western regulatory standards are lacking. Anyone considering combining Selank with psychiatric medication should consult a healthcare provider.

How does intranasal delivery reach the brain?

Intranasal delivery bypasses the blood-brain barrier through olfactory and trigeminal nerve pathways, providing more direct access to the central nervous system. This is the pharmacological rationale for the intranasal route and why it is the preferred administration method in clinical practice.

How does Selank compare to established anxiety treatments like SSRIs?

Selank and SSRIs work through different mechanisms (GABAergic/enkephalinergic vs. serotonin reuptake inhibition). SSRIs have vastly more clinical trial data, regulatory approval in multiple countries, and established long-term safety profiles. Selank’s evidence base is smaller and geographically concentrated. However, Selank’s lack of sexual side effects, weight gain, and discontinuation syndrome (common SSRI issues) is part of its appeal for those who have explored it.

Is the Russian clinical data trustworthy?

This is a legitimate question. Russian pharmaceutical research has produced valid science, but methodological standards, publication practices, and peer review processes can differ from Western norms. The absence of independent replication by research groups outside Russia is the most significant limitation of the Selank evidence base.

References

1. Zozulya AA, et al. “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.” Bull Exp Biol Med. 2008;145(4):462-5. PubMed
2. Kasian A, et al. “Selank administration affects the expression of some genes involved in GABAergic neurotransmission.” Front Pharmacol. 2017;8:668. PubMed
3. Inozemtseva LS, et al. “Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus.” Dokl Biol Sci. 2008;421:241-3. PubMed
4. Kozlovskii II, Danchev ND. “The anxiolytic effect of selank and its interactions with diazepam.” Neurosci Behav Physiol. 2003;33(3):255-8.
5. Seredenin SB, et al. “Anxiolytic and nootropic effect of selank.” Eksp Klin Farmakol. 2009;72(4):8-12.
6. Ershov FI, et al. “Antiviral activity of immunomodulator Selank in experimental influenza infection.” Vopr Virusol. 2009;54(5):19-24. [research needed — English translation availability]

Related Articles

Peptide

Epithalon (Epitalon): Research, Mechanism, and a Careful Look at the Anti-Aging Evidence

An evidence-based review of Epithalon — the tetrapeptide studied for telomerase activation, melatonin restoration, and lifespan extension. What the data supports and where it falls short.

Peptide

DSIP (Delta Sleep-Inducing Peptide): Research, Mechanism, and Evidence for Sleep Modulation

An evidence-based review of DSIP — the nonapeptide studied for delta wave sleep enhancement, stress hormone regulation, and neuroendocrine modulation. What the data shows and what remains unknown.

Peptide

KPV: What the Research Shows About This Anti-Inflammatory Tripeptide

An evidence-based review of KPV peptide — research on anti-inflammatory effects, gut health, NF-κB inhibition, and antimicrobial activity.